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Abstract
Background Early clinical trials for gene therapy of human gliomas with
retroviral packaging cells (PC) have been hampered by low transduction
efficacy and lack of dissemination of PC within the tumor. In the current
approach, these issues have been addressed by creating a stable packaging
cell line for retroviral vectors pseudotyped with glycoproteins of lymphocytic
choriomeningitis virus (LCMV) based on tumor-infiltrating progenitor cells.
Methods Tumor-infiltrating progenitor cells, which had been isolated from
adult rat bone marrow (BM-TIC), were modified to stably express Gag-Pol
proteins of moloney murine leukemia virus (Mo-MLV) and glycoproteins of
LCMV. Packaging of a retroviral vector was measured by titration experiments
on human fibroblast cells as well as on mouse and human glioma cell lines.
Additionally, gene transfer was tested in a rat glioma model in vivo.
Results The BM-TIC-derived packaging cell line (BM-TIPC) produced
retroviral vectors with titers between 2–8× 103 transducing units (TU)/ml.
Extended culturing of BM-TIPC over several weeks and freezing/thawing
of cells did not affect vector titers. No replication-competent retrovirus was
released from BM-TIPC. In a rat glioma model, BM-TIPC infiltrated the
tumors extensively and with high specificity. Moreover, BM-TIPC mediated
transduction of glioma cells in vivo.
Conclusion This proof-of-principle study shows that primary adult
progenitor cells with tumor-infiltrating capacity can be genetically modified
to stably produce retroviral LCMV pseudotype vectors. These BM-TIPC may
be a useful tool to enhance specificity and efficacy of gene transfer to gliomas
in patients. Copyright  2007 John Wiley & Sons, Ltd.
Introduction
Malignant gliomas are the most frequent primary brain tumors in adults and
are associated with a high mortality rate [1]. These tumors are typically highly
resistant to radiation and chemotherapy. Moreover, the infiltrative growth
pattern of gliomas does not allow complete tumor resection [2].
Early gene therapy trials were initiated to find alternative treatment
strategies to relieve the dismal prognosis of glioma patients. In these
trials, retroviral vectors were produced in situ by packaging cells (PC)
grafted into the tumor or the resection cavity. The retroviral vectors
produced by these PC encoded the suicide gene herpes simplex virus thymi-
dine kinase (HSV-tk), which renders transduced tumor cells sensitive to
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the prodrug ganciclovir. Despite very promising results in
animal models [3–5], these trials failed in the clinical
setting [6,7]. The major reason for this failure was
that the mode of vector delivery did not allow efficient
transduction of larger tumors or specific targeting of
infiltrating glioma cells [8].
Neural stem cells (NSC) have been proposed for
delivery of therapeutic molecules in vivo. NSC infiltrate
gliomas in vivo after intratumoral injection and colocalize
with invasive tumor cells [9–11]. Similar to NSC, stem
cells of non-neural origin have shown to specifically
infiltrate gliomas without migrating into normal brain
tissue [12–14]. Accordingly, we recently found that a
subpoplation of mesenchymal stem cells (MSC) infiltrate
gliomas in vivo with high efficacy and specificity (Miletic,
Fischer et al., submitted). This cell type was isolated from
adult rat bone marrow according to the protocol for
generating multipotent adult progenitor cells (MAPC)
published by Jiang and collegues [15]. We subsequently
referred to these cells as bone-marrow-derived tumor-
infiltrating cells (BM-TIC). Unlike most types of adult
progenitor cells, BM-TIC have a very high expansion
capacity in vitro. Rapid and extensive expansion is
required to create retroviral packaging cell lines.
Provided that both efficient and glioma-specific delivery
of therapeutic vectors can be achieved, another critical
step is the efficient entry of the vector into the glioma cells.
In previous studies on glioma gene therapy, retroviral
vectors carried the amphotropic murine leukemia virus
(MLV) envelope protein. However, this envelope allows
transduction of human glioma cells with only moderate
efficiency. In contrast, transduction of glioma cells can
be enhanced by up to tenfold, if the amphotropic MLV
envelope protein is exchanged by the glycoproteins
of LCMV (LCMV-GP). Importantly, LCMV-GP is not
cytotoxic, so that stable and constitutive expression of
LCMV-GP in PC can be achieved [16,17]. Above all,
LCMV-GP-mediated gene transfer to normal brain cells
is extremely inefficient so that LCMV-GP pseudotypes
transduce glioma cells in the brain with great specificity
[17].
The present work describes the generation of stable
PC for retroviral LCMV-GP-pseudotyped vectors based
on BM-TIC. To establish this cell line, BM-TIC were
genetically modified to express Mo-MLV Gag-Pol proteins
and LCMV-GP. Viral vectors were produced in bulk
cultures of BM-TIC packaging cells (BM-TIPC) with titers
of 1–8× 103 transducing units (TU)/ml. BM-TIPC were
passaged in vitro over several weeks without loss of
vector titer. Replication-competent retrovirus (RCR) was
not detected in BM-TIPC. Moreover, BM-TIPC infiltrated
gliomas in vivo and mediated transduction of glioma
cells. This report is the first to show that PC for LCMV-
GP-pseudotyped retroviral vectors can be derived from
tumor-infiltrating progenitor cells and that these BM-TIPC
retain their specific migratory capacity and can be used
for specific vector delivery to gliomas in vivo.
Materials and methods
Cell lines
The human embryonic kidney cell line 293T (ATCC
number CRL-11 268), the human rhabdomyosarcoma
cell line TE671 (ATCC number CCL-136) and the rat
gliosarcoma cell line 9L (ATCC number CRL-2200) were
obtained from the American Type Culture Collection
(ATCC). 9L-DsRed cells were established by transduction
of 9L cells with the retroviral DsRed-encoding vector
pMP71DsRed as described previously [17]. The human
glioblastoma cell line G62 was a gift from Prof. M.
Westphal, University Hospital Hamburg, Germany. All
cell lines were maintained in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10% fetal calf
serum (FCS) and 1% glutamine and grown at 37 ◦C
in a humidified atmosphere of 5% CO2. Rat MSC were
kindly provided by Dr. C. Lange, UKE Hamburg, Germany,
and were cultured in Ham’s-F12 medium (Promocell,
Heidelberg, Germany) supplemented with 20% FCS.
BM-TIC isolation and characterisation
BM-TIC were prepared from bone marrow of rats
following a protocol previously described [15], with
minor modifications. Fisher 344 rats (4–6 weeks old,
female) were killed and femurs and tibias were collected.
Bone marrow tissue was flushed out using an 18G
syringe. A single-cell suspension was obtained and
seeded into a T-75 flask covered with fibronectin
(Sigma). Non-adherent cells were removed after 3 days
of culture. Culture medium consisted of 60% DMEM/LG
(Gibco), 40% MCDB-201 (Sigma) with 2% fetal bovine
serum (FBS) (Pan Biotech), penicillin/streptomycin,
50 nM dexamenthasone (Sigma), 10−4 M ascorbic acid
2-phosphate (Sigma), linoleic acid-bovine serum albumin
0.5 mg/ml (Sigma), 1 × insulin transferrin selenium
(Gibco), and was supplemented with 10 ng/ml platelet-
derived growth factor-BB (Sigma), 10 ng/ml epidermal
growth factor (Sigma) and 1000U/ml leukemia inhibitory
factor (Chemicon). Cells were grown at 37 ◦C in 5% CO2
and maintained at low density by subculturing the cells
every third day.
Antibody staining and flow cytometric
analysis of BM-TIC and MSC
Rat-specific antibodies against CD44 (clone Ox-49), CD45
(clone Ox-1) and MHC class I (clone Ox-18) were
purchased from BD Pharmingen (Heidelberg, Germany).
For flow cytometric analysis, 3× 105 cells were incubated
for 30 min with 1 µg of primary antibody at room
temperature. Cells were then washed three times with
phosphate-buffered saline (PBS) containing 3% FBS and
incubated for an additional 20 min with the approriate
APC-conjugated secondary antibody in a dilution of 1 : 50.
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Cell-surface expression of the respective antigens was
analyzed by flow cytometry on a FACSCalibur (Becton
Dickinson, San Jose, CA, USA).
Construction of the lentiviral SIN
vector encoding LCMV-GP
A synthetic LCMV-GP gene with optimized codons was
obtained fromGeneart GmbH, Regensburg, Germany. The
LCMV-GPopt gene was cloned into EcoRI and NotI sites of
pLCMV-GP-IRES-Puro, which was a gift from Dr. Winfried
Beyer, University of Kiel, Germany [18]. The LCMV-
GPopt/IRES/Puro cassette was inserted into pBluescript
(Stratagene). From there, the LCMV-GPopt/IRES/Puro
cassette was excised by BamHI and XhoI digestion
and ligated into pHR’SIN-SEW to replace the eGFP
gene [19]. The resulting lentiviral self-inactivating (SIN)
vector pHR’SIN-GPopt contained an internal spleen focus
forming virus (SFFV) promoter and allowed coexpression
of LCMV-GPopt and the puromycin resistance gene
(PuroR) via the internal ribosomal entry site (IRES).
Retroviral vector production by
transient transfection of 293T cells
The 293T cell line was used for transient production
of gammaretroviral or lentiviral vectors. For production
of gammaretroviral vectors, the retroviral vector plasmid
MP71-eGFP-wPRE [20] was cotransfected with the Gag-
Pol expression plasmid pSV-Mo-MLVgagpol and the
envelope expression plasmid pHCMV-LCMV-GP [16]
into 293T cells. Lentiviral vectors were generated by
cotransfecting 293T cells with the lentiviral vector plasmid
pHR’SIN-GPopt (5 µg), the HIV Gag-Pol expression
plasmid pCMV-dR8.91 (15 µg) [21] and pHCMV-LCMV-
GP (2 µg). Forty-eight hours after transfection, cell culture
supernatants containing retroviral vectors were collected
and filtered through 45 µM pore size filters. Vector
supernatants were used directly to infect BM-TIC and
other cell lines, or stored at −80 ◦C.
Titration of retroviral vectors
Titration of gammaretroviral and lentiviral LCMV-GP
pseudotype vectors was performed on TE671 cells.
Titration of vectors produced in BM-TIPC was additionally
performed on 9L and G62 cells. Serial dilutions of vector
supernatants were prepared and 0.5 ml of each dilution
was added to 5× 104 cells seeded in a well of a 24-
well plate. Plates were centrifuged for 1 h at 1000 g.
For titration of vectors carrying the enhanced green
fluorescent protein (eGFP) gene, cells were analyzed
for eGFP expression 65 h after transduction by flow
cytometry. For vectors carrying the LCMV-GP gene,
cells were stained with a LCMV-GP-specific antibody
as described below and analyzed by flow cytometry.
All flow cytometry measurements were performed on
a FACSCalibur (Becton Dickinson) using the CellQuest
Pro software. Titers were calculated from dilutions which
resulted in 0.5 to 20% of transduced cells. Within this
range, a linear correlation between vector input and
percentage of transduced cells can be expected.
Generation of a BM-TIC packaging cell
line
For stable transfection of BM-TIC with the Mo-MLV Gag-
Pol expression plasmid pGag-Pol-IRES-bsr [18], cells were
seeded into 24-well plates at 1× 103 cells/well 2 days
before transfection. Transfection was performed using
the lipophilic reagent TransFectin (BioRad, Germany)
according to the manufacturer’s instructions. For each
well, 1 µg of plasmid DNA was used for transfection. Cells
were incubated with DNA for 6 h, after which medium
was changed. Forty-eight hours after transfection, BM-TIC
were trypsinized, plated into 10 cm dishes andmaintained
in selection medium containing blasticidin (5 µg/ml).
After 10 days, colonies were harvested using sterile Q-tips
and maintained as individual clones in selection medium.
For transduction of BM-TIC with the lentiviral vector
pHR’SIN-GPopt or the gammaretroviral vector MP71-
eGFP-wPRE, BM-TIC were plated into 24-well plates at
5× 103 cells/well on the day before transduction. The fol-
lowing day, medium was replaced with vector-containing
supernatants. Plates were centrifuged for 1 h at 37 ◦C
and 1000 g. Fresh medium was added 6 h after transduc-
tion. For BM-TIC transduced with pHR’SIN-GPopt, cells
were trypsinized 48 h after transduction and plated into
10 cm dishes in selection medium containing puromycin
(2.5–5 µg/ml). For BM-TIC transduced with MP71-eGFP-
wPRE, cells were analysed for eGFP expression 48 h after
transduction by flow cytometry.
BM-TIC packaging cells (BM-TIPC) expressing both
pGag-Pol-IRES-bsr and pHR’SIN-GPopt were perma-
nently maintained under selection with puromycin and
blasticidin (5 µg/ml each). To test vector production
in BM-TIPC, cells were seeded into 6-well plates at
5× 104 cells/well in 2 ml of medium without selection
antibiotics. The next day, cell culture medium of BM-TIPC
was used to transduce TE671 cells as described above.
Flow cytometric analysis of Gag and
LCMV-GP expression
Expression of Mo-MLV Gag and LCMV-GP in BM-TIC was
assessed by flow cytometric analysis. For Gag detection,
1× 106 cells were harvested, fixed and permeabilized
using the Fix&Perm Kit (Caltag). Staining for intracellular
Gag was performed with a polyclonal anti-p30 rabbit
serum, which was kindly provided by Dr. Carol Stocking,
University Clinic Hamburg-Eppendorf, Germany. The
secondary antibody was a phycoerythrin (PE)-conjugated
Fab-anti-rabbit (Caltag). For LCMV-GP detection, 5× 105
BM-TIC were harvested and fixed with 3% formaldehyde.
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LCMV-GP on the cell surface was stained with the
monoclonal antibody KL25 [22] and the PE-conjugated
goat-anti-mouse serum (Caltag).
Test for replication-competent
retrovirus
A sensitive polymerase chain reaction (PCR)-based assay
was applied to test the presence of replication-competent
retrovirus (RCR) in BM-TIPC supernatants. TE671 cells
were plated into 24-well plates at 5× 104 cells/well
and transduced with 0.5 ml supernatant of BM-TIPC.
As positive control, TE671 cells were transduced with
supernatants from cells infected with amphotropic MLV
(A-MLV). TE671 cells were then incubated for 9 days.
After this period, cell culture supernatants from TE671
cells were used to infect fresh TE671 cells. After 48 h,
TE671 cells were harvested, genomic DNA was isolated
using the DNeasy Kit (Qiagen) and used as templates
for PCR. Primers pairs used to amplify actin, Mo-MLV
Gag, amphotropic MLV envelope protein (A-MLVenv) and
LCMV-GP sequences were: actin 5′ GCT CGT CGT CGA CAA
CGG CTC 3′ and 5′ CAA ACA TGAT CTG GGT CAT CTT CTC
3′; Mo-MLV Gag 5′ CTT CCT AGA GAG ACT TAA GG 3′ and
5′ GTT GGG ACC TCC TTC GTT CTC 3′ [23]; A-MLVenv 5′
TGT AAC CTG GAG AGT CAC CAA C 3′ and 5′ CTC CGA CCA
GAT CAC ATA GAT C 3′; LCMV-GP 5′ GCA GCC AGA CCA
GCT ACC 3′ and 5′ GCT GTT CAC GGT GGT CTT G 3′. The
annealing temperature was 53 ◦C. For each reaction, 40
amplification cycles were performed. PCR products were
subjected to agarose gel electrophoresis in the presence
of ethidium bromide and visualized under UV light.
Animal experiments
Adult female Fisher 344 rats (Harlan Winkelmann,
Borchen, Germany) were anesthetized with intraperi-
tonal (i.p.) injection of ketamine (50 mg/kg) and xylazine
(2 mg/kg). Intracranial 9L-DsRed tumors were estab-
lished by injection of 8× 104 9LDsRed cells (in 2 µl
PBS) into the right striatum using a Hamilton syringe in
a stereotaxic apparatus (Stoelting, IL, USA). The coordi-
nates used were 4 mm lateral to the bregma and 5 mm in
depth to the dural surface. Five days after tumor implan-
tation, rats were anesthetized, and 4× 105 BM-TIPC were
injected using the same stereotactic coordinates. For
control experiments, BM-TIC expressing only the gam-
maretroviral eGFP vector or the eGFP vector and the
lentiviral LCMV-GP vector were injected into rat tumors
as described above. After 7 days, animals were eutha-
nized and perfused with 4% paraformaldehyde. Brains
were removed, suspended in 30% sucrose for 3 days,
and then snap-frozen in isopentane chilled with liquid
nitrogen. Coronal sections (12 µm) were prepared on a
cryostat and examined under a fluorescence microscope
(Zeiss, Jena, Germany). In addition, sections were ana-
lyzed by confocal scanning laser microscopy (Leica, UK)
to detect in vivo transduction of tumor cells. Transduction
efficiencies in infected tumor areas were determined by
counting cells on confocal microscopic images from three
different animals.
Results
Isolation and characterization of
BM-TIC
Tumor-infiltrating progenitor cells were isolated from
adult rat bone marrow following a protocol established
by Jiang et al. [15] to derive multipotent adult progenitor
cells (MAPC). BM-TIC proliferated with a population dou-
bling time of approximately 24 h and could be expanded
for more than 60 passages without apparent signs of
senescence (data not shown). To further characterize
BM-TIC, expression of major histocompatibility complex
class I (MHC I), CD44 and CD45 was assessed. As shown
in Figure 1, BM-TIC are negative for MHCI, CD44 and
CD45, thereby resembling MAPC [15]. In contrast, rat
MSC express both MHCI and CD44, as previously reported
[24].
Genetic modifications of BM-TIC to
create a packaging cell line for
gammaretroviral LCMV-GP pseudotypes
To create a BM-TIC-based packaging cell line (BM-TIPC)
for LCMV-GP pseudotypes, Mo-MLV Gag-Pol and LCMV-
GP genes were introduced into BM-TIC. As a first step, BM-
TIC were transfected with the Mo-MLV gag-pol expression
plasmid pGag-Pol-IRES-bsr (Figure 2), which coexpresses
a blasticidin resistance gene and Mo-MLV gag-pol via an
IRES. Clones were grown in selection medium and exam-
ined by flow cytometry for Mo-MLV Gag expression. Gag
expression in clone BM-TIC-C1 is shown in Figure 3A.
To achieve stable LCMV-GP expression in BM-TIC, the
lentiviral self-inactivating (SIN) vector pHR’SIN-GPopt
with internal SFFV promoter and LCMV-GP/IRES/Puro
cassette was created (Figure 2). BM-TIC-C1 were trans-
duced with pHR’SIN-GPopt and subsequently transferred
to selection medium. Transduced BM-TIC were expanded
as bulk cultures without isolating single clones. LCMV-
GP expression in BM-TIC-C1/GP was confirmed by flow
cytometry at two different time points after transduc-
tion. As shown in Figure 3B, LCMV-GPopt expression
was detectable in BM-TIC-C1/GP and remained stable
during 10 weeks of culture. The gammaretroviral vec-
tor MP71-eGFP-wPRE (Figure 2) was then introduced
by transduction into BM-TIC-C1/GP to create BM-TIPC.
Expression of the eGFP was determined by flow cytometry
and was present in >90% of cells (data not shown).
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Figure 1. Staining of BM-TIC and MSC for cell-surface antigens. BM-TIC and MSC were stained with antibodies against CD44, CD45
or MHC I and with APC-conjugated secondary antibodies. Control samples were stained with secondary antibody only. Samples
were analyzed by flow cytometry
Figure 2. Packaging constructs used to establish BM-TIPC. Promoters are shown as white arrows, open reading frames as grey
boxes. The bicistronic expression plasmid pGag-Pol-IRESbsr (A) encodes Mo-MLV Gag-Pol and confers blasticidin resistance (bsr)
to stable transfectants. The bicistronic lentiviral vector pHR’SIN-Gpopt (B) encodes a codon optimized LCMV-GP together with
a puromycin resistance gene (Puro). The 3′ HIV LTR has a deletion in the U3 region, which leads to self-inactivation of the
promoter activity of the HIV LTR during reverse transcription. This prevents remobilization of the integrated lentiviral vector from
the host cell. Transgene expression from pHR’SIN-Gpopt is driven by an internal SFFV promoter. The gammaretroviral reporter
construct MP71-eGFP-wPRE (C) contains intact LTRs and the gammaretroviral packaging signal ! and encodes the enhanced green
fluorescent protein (eGFP). EF1a: elongation factor 1a promoter; IRES: internal ribosomal entry site from Encephalomyocarditis
virus; LTR: long terminal repeats; MPSV: myeloproliferative sarcoma virus; SFFV: U3 promoter/enhancer region of the spleen focus
forming virus; wPRE: woodchuck hepatitis virus posttranscriptional regulatory element
Vector production in BM-TIPC and
transduction of glioma cell lines in
vitro
Efficiency and stability of vector production in BM-TIPC
was tested by titration of supernatants on TE671 cells.
Vector titers ranged between 1.3× 103 and 7.9× 103
TU/ml and remained stable over 1 month in culture
and after several cycles of freezing/thawing of BM-TIPC
(Figure 4A). Vector titers on 9L rat glioma cells and G62
human glioma cells were subsequently measured. Vectors
produced in BM-TIPC mediated transduction of both
glioma cell lines in vitro. The efficiency of transduction of
9L cells was comparable to TE671, whereas G62 human
glioma cells were transduced with about 4-fold higher
efficiency (Figure 4B).
The presence of replication-competent retrovirus (RCR)
in BM-TIPC supernatants was tested in a PCR-based
assay (refer to ‘Material and methods’ section), which
in previous studies reproducibly detected RCR in positive
controls (i.e. cell lines producing amphotropic replication-
competent MLV) and which is more sensitive than
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Figure 3. Expression of MLV Gag and LCMV-GPopt in BM-TIC. (A) Gag expression in BM-TIC after stable transfection with
pGag-Pol-IRES-bsr was determined by intracellular staining with an anti-p30 antibody and a PE-conjugated secondary antibody.
(B) Expression of LCMVGP in BM-TIC-C1 after transduction with pHR’SIN-GPopt was determined by staining of the cell surface with
an a-LCMV-GP primary antibody (KL25) and a PE-conjugated secondary antibody. Staining against LCMV-GP was performed at two
different time points (day 48 and day 72) after transduction. Samples were analyzed by flow cytometry
Figure 4. Production of retroviral vectors by BM-TIPC. (A) Cell culture supernatants from BM-TIPC were used to transduce TE671
cells at indicated time points after transduction with MP71-eGFP-wPRE. (∗) BM-TIPC had undergone three cycles of freezing/thawing.
(B) Vectors produced in BM-TIPC were titrated on TE671, 9L rat glioma and G62 human glioma cell lines in parallel. Data are
shown as mean values and standard deviations from three independent experiments
the commonly used marker rescue assay (our own
unpublished observations). BM-TIPC supernatants were
free of any detectable RCR, as demonstrated by lack
of MLV Gag, A-MLVenv and LCMV-GPopt sequences in
genomic DNA of TE671 indicator cells (Supplementary
Figure S1, see Supplementary Material).
Glioma-specific migration of BM-TIPC
and transduction of glioma cells in vivo
For generation of the BM-TIPC, foreign (viral and non-
viral) genes were introduced and the cells were expanded
for numerous passages in vitro. The ability of these
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Figure 5. BM-TIPC infiltrate gliomas in vivo with high specificity and efficacy. BM-TIPC were injected intratumorally into established
9L-DsRed gliomas in Fischer rats. After 7 days, rats were killed, brain sections were prepared and analyzed by fluorescence
microscopy. Panels A, B and C represent sections from three different tumors injected with BM-TIPC. Magnification 2.5×, white
arrows indicate the site of injection of BM-TIPC
extensively manipulated BM-TIPC to specifically infiltrate
gliomas in vivo was analyzed. BM-TIPC were injected
into established 9L-DsRed gliomas in Fischer rats. After
7 days, examination of brain sections revealed an efficient
infiltration of gliomas by BM-TIPC (Figure 5). BM-TIPC
migrated far away from the injection site (indicated
by arrows in Figures 5A and 5C) and infiltrated large
proportions of the tumor. Moreover, the migratory
behavior of BM-TIPC was highly specific for gliomas, as
no BM-TIPC infiltration into normal brain was observed.
Transduction of glioma cells in vivo was examined
by confocal microscopy on the same brain sections.
Colocalization of green and red fluorescence, indicative
of transduced glioma cells, was detected in both solid
(Figure 6A) and infiltrating (Figure 6B) tumor areas. In
contrast, when BM-TIC expressing the gammaretroviral
eGFP vector alone or together with LCMV-GP but lacking
Mo-MLV Gag-Pol were injected into rat gliomas, no
presence of red and green fluorescence in the same
cell could be detected (Figures 6D and 6E). This shows
that only BM-TIPC with complete packaging function can
transfer the retroviral vector to glioma cells and that
the colocalization of red and green fluorescence was not
a result of cell fusion or uptake of fluorescent proteins
from surrounding cells. The percentage of transduced
glioma cells reached up to 33% in some tumor areas.
This shows that BM-TIPC continue to produce retroviral
vectors in vivo and facilitate glioma cell transduction.
Importantly, BM-TIPC were also found adjacent to single
infiltrating glioma cells and mediated their transduction
(Figure 6C, arrow).
Discussion
The success of gene therapy for gliomas depends
primarily on the efficient and glioma-specific transfer
of the therapeutic gene. By injecting fibroblast-based
packaging cells (PC), efficient tumor cell transduction
can be achieved in animal models but not in clinical
settings, due to the non-migratory character of these PC
[6]. Stem cells of neural and non-neural origin can be
used to deliver therapeutic molecules to gliomas in vivo
[9,10,12]. However, the expression of toxic genes only
in the tumor-infiltrating cells but not the tumor itself
may not be sufficient to achieve a sufficient therapeutic
effect for the treatment of human gliomas. The aim of
the present work was therefore to create a PC based on
glioma-infiltrating progenitor cells. Most adult progenitor
cells, like neural and mesenchymal stem cells, however,
have only limited expansion capacity unless immortalized
with oncogenes. This limited expansion impedes the
establishment of clonal PC and the production of large
PC batches for clinical applications. In the present
study, we used tumor-infiltrating progenitor cells with
a high intrinsic expansion capacity to establish stable
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Figure 6. BM-TIPC mediate in vivo transduction of rat glioma cells. BM-TIPC were injected intratumorally into established
9L-DsRed gliomas in Fischer rats. After 7 days, rats were killed, brain sections were prepared and analyzed by confocal microscopy.
Colocalization of green and red fluorescence demonstrates tumor cell transduction. Shown are images from solid (A) and infiltrating
(B, C) tumor areas in which tumor tranduction could be readily detected. The white arrow in (C) indicates an infiltrating transduced
glioma cell in close proximity to BM-TIPC. Injection of BM-TIC expressing only the gammaretroviral eGFP vector (D) or the
gammaretroviral eGFP vector and LCMV-GP (E) did not result in colocalization of green and red fluorescence. Magnification 40×
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PC. Progenitor cells were isolated from adult rat bone
marrow according to a protocol established by Jiang and
collegues [15] to isolate multipotent adult progenitor
cells (MAPC). MAPC have the capability to differentiate
into various cell types in vitro and in vivo. Moreover,
MAPC have a very high expansion capacity and can be
expanded to more than 100 population doublings without
requiring exogenous immortalization [15]. Although the
differentiation capacity of the BM-TIC was not analyzed in
this study, marker expression and expansion capacity of
BM-TIC strongly resemble that of MAPC. To establish
BM-TIC-based PC, BM-TIC were genetically modified
to express Mo-MLV Gag-Pol and LCMV-GPopt. The
glycoprotein of LCMV was chosen because LCMV-GP
mediates up to tenfold higher transduction rates in human
glioma cell lines than the amphotropic retroviral envelope
protein [16,25]. The expression of viral membrane
proteins is often associated with cytotoxicity. Thus,
the generation of PC for vectors pseudotyped with the
glycoprotein of vesicular stomatitis virus (VSV-G) is
hampered by the toxicity of VSV-G and requires inducible
expression systems [26]. In contrast to VSV-G, LCMV-GP
can be stably expressed in cell lines without causing
cytotoxicity [16]. Moreover, LCMV-GP was shown to
specifically mediate gene transfer to glioma cells but not to
neuronal cells, while VSV-G was found to preferentially
target neuronal cells [17]. A lentiviral self-inactivating
(SIN) vector encoding LCMV-GP was created and used to
transduce bulk cultures of BM-TIC. This led to stable and
prolonged LCMV-GP expression in BM-TIC over more
than 2 months in culture. Titers achieved on human
glioma cells reached 1× 104 TU/ml and are therefore
comparable to vector titers of PC used in previous clinical
studies [27]. Importantly, as a consequence of tumor
infiltration by BM-TIPC, local vector titers throughout the
tumor are expected to be higher than titers achieved by
injecting non-migratory PC.
When tested for glioma-specific migration in vivo, BM-
TIPC behaved similarly to the parental BM-TIC cell
line (Miletic, Fischer et al., submitted): after a single
intratumoral injection, BM-TIPC were detected in most
tumor areas, but never in normal brain parenchyma.
This shows that BM-TIPC retain their glioma-specific
migratory capacity even after extensive culturing, genetic
modification and subcloning. One important option for
clinical application of BM-TIPC is their injection into
gliomas during stereotactic biopsy. The very efficient
tumor infiltration by BM-TIPC may then lead to
widespread distribution of viral vectors within human
gliomas and ensure the targeting of tumor cells distant
from the injection site. This targeting of distant tumor cells
can currently not be achieved by injection of replication-
incompetent vectors due to only limited vector diffusion
[6].
In a rat glioma model, tranduction was detected in
both solid and infiltrating tumor regions, showing that
BM-TIPC application is a suitable method to achieve
gene transfer into glioma in vivo. Interestingly, BM-TIPC
colocalized with single invasive glioma cells and mediated
transduction of these cells. Invasive glioma cells migrating
into normal brain parenchyma are a major problem in
glioma therapy, as they are not accessible to surgery
and typically give rise to tumor spread and regrowth.
Transduction efficiencies achieved by BM-TIPC injection
varied, ranging from undetectable to up to 33% of
transduced glioma cells in different areas of the same
glioma. In future experiments, the transduction efficiency
in vivomay be enhanced by using lentiviral vectors instead
of Mo-MLV-based gammaretroviral vectors. In contrast to
gammaretroviral vectors, lentiviral vectors do not depend
on cell proliferation for efficient transduction. Lentiviral
gene transfer may thus enhance transduction of tumor
areas with low proliferation rate. Specific gene transfer
into glioma cells, but not into healthy brain, may thereby
be achieved by pseudotyping lentiviral vectors with LCMV-
GP [17].
In conclusion, the present study is the first to show
that primary adult progenitor cells can be modified
to stably produce retroviral LCMV pseudotype vectors
while maintaining their high expansion capacity and their
specific tropism for gliomas. In the presented model,
specificity of gene transfer is conferred by the glioma-
specific infiltration of the progenitor cells and by the
selective tropism of LCMV-GP-pseudotyped vectors for
glioma cells. In future studies, the efficiency of BM-
TIPC-mediated gene transfer, shown here for the eGFP
marker gene only, needs to be determined for therapeutic
genes and extended to human glioma models. Provided
that BM-TIPC show a good efficiency in these follow-up
experiments, we are confident that these novel progenitor-
cell-based packaging cells will be a valuable tool for gene
therapy of human gliomas.
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